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Extracellular vesicles (EVs) are specifically loaded with nucleic acids, lipids, and pro-
teins from their parental cell. Therefore, the constitution of EVs reflects the type and 
status of the originating cell and EVs in melanoma patient’s plasma could be indicative 
for the tumor. Likewise, EVs might influence tumor progression by regulating immune 
responses. We performed a broad protein characterization of EVs from plasma of mela-
noma patients and healthy donors as well as from T cells, B cells, natural killer (NK) cells, 
monocytes, monocyte-derived dendritic cells (moDCs), and platelets using a multiplex 
bead-based platform. Using this method, we succeeded in analyzing 58 proteins that 
were differentially displayed on EVs. Hierarchical clustering of protein intensity patterns 
grouped EVs according to their originating cell type. The analysis of EVs from stimulated 
B cells and moDCs revealed the transfer of surface proteins to vesicles depending on 
the cell status. The protein profiles of plasma vesicles resembled the protein profiles of 
EVs from platelets, antigen-presenting cells and NK cells as shown by platelet markers, 
co-stimulatory proteins, and a NK cell subpopulation marker. In comparison to healthy 
plasma vesicles, melanoma plasma vesicles showed altered signals for platelet markers, 
indicating a changed vesicle secretion or protein loading of EVs by platelets and a lower 
CD8 signal that might be associated with a diminished activity of NK cells or T cells. As 
we hardly detected melanoma-derived vesicles in patient’s plasma, we concluded that 
blood cells induced the observed differences. In summary, our results question a direct 
effect of melanoma cells on the composition of EVs in melanoma plasma, but rather 
argue for an indirect influence of melanoma cells on the vesicle secretion or vesicle 
protein loading by blood cells.
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Abbreviations: APC(s), antigen-presenting cell(s); BCA assay, bicinchoninic acid assay; BSA, bovine serum albumin; CCR7, 
C–C chemokine receptor type 7; CD, cluster of differentiation; CXCR4, C–X–C chemokine receptor type 4; D, donor; DC, den-
dritic cell; EDTA, ethylenediaminetetraacetate; ELISA, enzyme-linked immunosorbent assay; EV(s), extracellular vesicle(s); 
GM-CSF, granulocyte-macrophage colony-stimulating factor; GPI, glycosylphosphatidylinositol; HLA(-ABC, DP, DQ, DR), 
human leukocyte antigen (type ABC, DP, DQ, DR); ICAM-1, intercellular adhesion molecule 1; iDC(s), immature dendritic 
cells(s); IL, interleukin; MCSP, melanoma-associated chondroitin sulfate proteoglycan; Mel-CAM, melanoma cell adhesion 
molecule; MHC, major histocompatibility complex; moDC(s), monocyte-derived dendritic cell(s); NK cell(s), natural killer 
cell(s); NTA, nanoparticle tracking analysis; PAP, PBS supplemented with 0.1% pluronic and 0.09% azide; PGE, prostaglandin; 
ROR1, tyrosine protein kinase transmembrane receptor.
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inTrODUcTiOn
Exosomes are extracellular vesicles (EVs) that are formed by 
inward-budding of late endosomes that fuse with the plasma 
membrane to release exosomes. Therefore, exosomes exhibit the 
same membrane orientation as cells by displaying membrane 
bound proteins on their surface (1, 2). Exosomal proteins are 
transferred from complexes involved in exosome biogenesis, such 
as the tetraspanin CD63 (3) or from the originating cell mem-
brane (2). Tetraspanin proteins are, therefore, used as exosome 
markers (4, 5) and cell-type-specific markers on exosomes are 
thought to indicate the originating cell type (6).
In melanoma patients, the amount of plasma exosomes was 
reported to be increased in comparison to healthy donors (7). This 
raises the question whether the surplus of exosomes derives from 
the tumor itself or from blood cells. Melanoma-derived exosomes 
can prevent anti-tumor immune responses by promoting the gen-
eration of an immunosuppressive cell subset (8) and are able to 
promote tumor progression (9). Tumor-derived exosomes were 
found to be immunosuppressive as well as immune activating. 
On the one hand, tumor exosomes inhibit the activity of natural 
killer (NK) cells and cytotoxic T cells (10, 11) or induce apoptosis 
of T cells by galectin-9 or Fas ligand (12–14). On the other hand, 
they are able to activate cytotoxic T cells via tumor antigens after 
being loaded onto dendritic cells (15, 16).
Since Caby and colleagues found exosomes in human 
blood, platelets are considered as major contributors to the 
EV pool found in plasma (17). Major histocompatibility com-
plex (MHC) class II and CD86 on plasma exosomes point at 
antigen-presenting cells (APCs) as exosome source (17, 18). 
Additionally, activated cells have to be taken into account 
as cell stimulation alters the protein loading or secretion of 
exosomes from B cells (19) and T cells (20, 21), respectively. 
The contribution of different cell types to the pool of plasma 
EVs is considered important because blood cell-derived EVs are 
known to modulate immune responses and tumor progression 
in various ways [for a review, see Ref. (1, 22)].
Uncovering the parental cells of plasma EVs might give insight 
into the intercellular communication between melanoma cells 
and immune cells. This requires that plasma EVs actually carry 
cell-type-specific markers enabling the identification of their 
parental cells. So far, most of the studies focused on exosomes 
released by a distinct cell type and differed in the applied methods 
for protein detection. For example, platelet EVs were character-
ized by electron microscopy (23) and mass spectrometry (24), 
while ELISA and flow cytometry were applied to investigate EVs 
from B cells (19, 25–28) and monocyte-derived dendritic cells 
(moDCs) (29–31). To achieve an extensive protein profiling 
of EVs from different sources, we isolated EVs from plasma of 
melanoma patients and healthy donors as well as from diverse 
blood cell types and analyzed them by a multiplex bead-based 
platform (32). We identified surface proteins on EVs that were 
adopted from parental cells and allowed to distinguish EV types 
secreted from different cell types.
Interestingly, from three markers, which were suggested as 
melanoma markers (33–35), only CD49e was detected in five out 
of eight melanoma plasma samples, whereas MSCP and CD146 
were hardly detectable on plasma EVs isolated from melanoma 
patients. This indicates that only a minor portion of plasma 
vesicles derive from melanoma cells. Still, we found that the signal 
intensities for five surface proteins differed between plasma EVs 
from healthy donors and melanoma patients. We suggest that 
tumor cells induce a change of the vesicle composition in plasma 
of melanoma patients by altering the EV secretion or EV protein 
loading of blood cells.
MaTerials anD MeThODs
cell isolation, culture, and stimulation for 
Vesicle Production
Melanoma cell lines were grown in RPMI1640 (biowest, L0501-
500) with 10% FCS (Biochrom, S  0415), 2  mM l-glutamine 
(Lonza, BE-17-605E), 50  U/ml penicillin, and 50 μg/ml strep-
tomycin (Thermo Scientific, SV30010). For EV production, the 
cells were washed with phosphate buffered saline (PBS) and 
cultured for 72 h in FCS-free medium to avoid any contamination 
with bovine EVs. The percentage of apoptotic cells (AnnexinV+, 
Miltenyi Biotec, 130-093-060) was below 5%.
The donors of whole blood, buffy coats, and leukapheresis that 
were used for the following cell isolations gave written informed 
consent in accordance with the Declaration of Helsinki.
Platelets were isolated from fresh whole blood that was diluted 
with an equal volume of Krebs Ringer buffer (100 mM NaCl, Th 
Geyer 1367, 4  mM KCl, AppliChem A1428, 20  mM NaHCO3, 
Merck 1063291000, 2 mM Na2SO4, Sigma Aldrich 403008-100G, 
4.7 mM citric acid, VWR EM-CX1723-1, 14.2 mM tri-sodium 
citrate, Merck 1.06448.1000) at pH 7.4 and centrifuged at 
190 × g for 10 min (23). To deplete leukocytes and erythrocytes 
the platelet-rich plasma was centrifuged at 100 × g for 20 min. 
Platelets were pelleted at 1,000 × g for 15 min and washed twice 
with Krebs Ringer buffer. 1 to 9  ×  107 platelets per milliliter 
whole blood were isolated and platelet purities ranged from 82 
to 99%. After adjusting to 1 ×  109 platelets per milliliter, they 
were activated with 50 nM Calcium Ionophore (Sigma Aldrich, 
C7522-1MG) and 10  mM calcium chloride (Sigma Aldrich, 
C3306-100G) for 30 min at room temperature (36).
T cells were isolated from Buffy Coats by Pan T Cell Isolation 
Kit (Miltenyi Biotec, 130-096-535) with purities of 96–99%. 
To generate as many EVs as possible the protocol by van der Vlist 
et al. was used with minor modifications (21). Briefly, cells were 
cultured in TexMACS medium (Miltenyi Biotec, 130-097-196) 
without serum with 5 U/ml IL-2 (Miltenyi Biotec, 130-097-743) 
and with 2.5  μg/ml CD28 (clone 15E8, Miltenyi Biotec Cat# 
130-093-375 Lot# RRID:AB_1036134) in CD3 (clone OKT3, 
Miltenyi Biotec Cat# 130-093-387 Lot# RRID:AB_1036144) 
coated tissue culture flasks for 24  h with viability rates >90%. 
After activation, 75–95% of T cells were positive for the T cell 
activation marker CD69 (Miltenyi Biotec Cat# 130-092-160 Lot# 
RRID:AB_615102).
Natural killer cells were isolated from buffy coats using the 
MACSxpress® NK Cell Isolation Kit and cultured in TexMACS 
GMP medium (Miltenyi Biotec, 170-076-309) with 5% human 
AB serum (Life Technologies, 34005100) and 500 U/ml Proleukin 
S (Novartis, 2238131) for 14 days.
3Koliha et al. Melanoma Affects Plasma EV Composition
Frontiers in Immunology | www.frontiersin.org July 2016 | Volume 7 | Article 282
Monocytes were isolated from Buffy coats after Ficoll gradi-
ent by immunomagnetic cell sorting using CD14 MicroBeads 
(Miltenyi Biotec, 130-050-201) with purities of 92–98% 
and  cultured in RPMI1640 (biowest, L0501-500) with 2  mM 
l-glutamine (Lonza, BE-17-605E), 50  U/ml Penicillin, and 
50 μg/ml Streptomycin (Thermo Scientific, SV30010) for 24  h 
with viability rates >90%.
To generate moDCs, monocytes were isolated from leukapher-
esis by immunomagnetic cell sorting using CliniMACS CD14 
Beads (Miltenyi Biotec, 272-01) and the CliniMACS Prodigy® 
system (Miltenyi Biotec, Germany). 2 to 6 × 106 monocytes per 
milliliter were cultured in RPMI (Lonza, BE12-167F) with 2 mM 
l-glutamine (Lonza, BE-17-605E), 1% autologous serum, 250 IU/
ml IL-4 (Miltenyi Biotec, 170-076-135), and 800 IU/ml GM-CSF 
(Miltenyi Biotec, 170-076-112). After 2 and 4  days, half of the 
medium was replaced by fresh medium adjusted to the same 
final cytokine concentrations. On day 6, half of the medium was 
replaced by fresh medium to reach final concentrations of 1 μg/
ml PGE2 (Merck, 538904-1MG), 1000  IU/ml TNF-α (Miltenyi 
Biotec, 170-076-103), 1000 IU/ml IL-6 (Miltenyi Biotec, 170-076-
104), and 200  IU/ml IL-1ß (Miltenyi Biotec, 170-076-102). To 
isolate EVs, supernatants of immature moDCs were harvested on 
day 2, 4, and 6, and supernatants from mature moDCs on day 7 
and 10.
B cells were isolated from Buffy coats after Ficoll gradient by 
immunomagnetic cell sorting using CD19 MicroBeads (Miltenyi 
Biotec, 130-050-301) with purities of 97–99%. 2 ×  106 B cells 
per milliliter were cultured in StemMACS HSC Expansion 
Media XF (Miltenyi Biotec, 130-100-473) with 5% EV-depleted 
human AB serum (Gemini, 100-512). To stimulate the cells, 
1 μg/ml CD40-Ligand, cross-linking antibody (Miltenyi Biotec, 
130-098-776), and 20 IU/ml IL-4 (Miltenyi Biotec, 130-093-919) 
were incubated for 30  min at room temperature before cells 
were added to the medium for 4 days. On the day of EV harvest, 
the viability rates were >90%. Eighty-five to 93% of activated B 
cells were positive for CD80 (Miltenyi Biotec Cat# 130-101-218 
Lot# RRID:AB_2571526) and 83–95% were positive for CD86 
(Miltenyi Biotec Cat# 130-100-100 Lot# RRID:AB_2571527).
Blood samples
Blood was obtained from healthy volunteers after written 
informed consent on nine different days with the safety blood 
collection set 21G x 3/4″ (Greiner, 450085) in vacutainers with 
0.105 M sodium citrate (BD, 366575) or 17 IU/ml heparin (BD, 
367526) as anticoagulant. For the isolation of platelets and plasma 
EVs, blood was anticoagulated with sodium citrate and donors 
had not consumed alcohol or ibuprofen in the last 24 h and did 
not use aspirin, heparin, or anti-histamines in the preceding 
2 weeks to exclude impacts of these drugs on platelet activation 
and exosome secretion. Donors were fasting to decrease lipopro-
teins that might sediment with EVs during ultracentrifugation 
and contaminate the sample. Blood was drawn at the same time 
of day (i.e., between 08:30 and 09:30 a.m.) to minimize circadian 
rhythm effects. The first 3 ml of blood were discarded to reduce 
contamination with activated platelets and fibroblasts. Donors 
were not pregnant. Blood was centrifuged 1 h after blood drawn 
at the latest.
After declaration of informed consent as approved by 
the Ethics Committee of the Friedrich-Alexander Universität 
Erlangen Nürnberg (Ethik-Kommission/Re.-No. 4602) blood from 
melanoma patients was collected with heparin as anticoagulant. 
Plasma was isolated and stored at −80°C until use.
Age, sex, smoking habit, and medication of the healthy 
donors and the melanoma patients are summarized in Table S2 
in Supplementaray Material.
isolation of extracellular Vesicles
Cell culture supernatants were depleted from cells and large cell 
debris by centrifugation at 2,000 × g for 30 min. Dead cells and cell 
debris were depleted by centrifugation at 10,000 × g for 45 min 
and larger vesicles by filtration through 0.22 μm membranes. EVs 
were pelleted at 108,000 × g for 2 h in a Beckman Avanti J30i 
centrifuge with an appropriate rotor (JA-30.50 Ti) and washed 
with PBS. To isolate plasma EVs whole blood was centrifuged at 
1,000 × g for 10 min. Plasma was diluted with an equal volume 
PBS before performing the centrifugation steps described above. 
Plasma EVs were filtrated through a 0.22  μm membrane in 
between the two ultracentrifugation steps at 108,000 × g for 2 h.
Extracellular vesicle pellets were resuspended in a minimal 
volume of PBS. The EV concentration was measured indirectly 
by BCA Protein Assay (Pierce, 23227) using BSA as standard.
nanoparticle Tracking analysis
Size distribution and concentration of EVs were measured with 
a Nano Sight LM10 instrument equipped with a 532  nm laser 
and an EMCCD camera (Malvern Instruments Ltd., UK). For 
data analysis, NTA software version 3.1 was used. All measure-
ments were carried out with optimized settings from the same 
experienced operator to achieve comparable results. EVs from 
different sources were serially diluted in essentially particle-free 
PBS. Concentration was calculated from the particle concentra-
tion step ideally suited for tracking analysis (ca. 5 × 108 particles/
ml) and the respective dilution factor. The value obtained this way 
together with the protein concentration of the diluted sample was 
used to calculate the protein amount per particle.
scanning electron Microscopy
Morphology and size of EVs were analyzed by scanning electron 
microscopy as described by Lui (37). Ten microgram primary 
melanoma EVs were diluted in 0.22 μm filtered PBS for a final 
volume of 50 μl and loaded on a silicon carrier. EVs were washed 
three times with 0.22 μm filtered PBS and fixed in 2% paraform-
aldehyde (Miltenyi Biotec, 130-090-477) for 10 min and washed 
again. Subsequently, EVs were fixed in 2.5% glutaraldehyde (Alfa 
Aesar, A17876) for 10 min and washed five times with distilled 
water. Before imaging, a MED010 sputter was used to sputter 
coat the sample with gold–palladium for 90  s. A Zeiss Supra 
55 Scanning Electron Microscope (Zeiss, Germany) was used 
at a voltage of 2 kV. The diameter of 100 EVs was measured to 
determine the average size by using the software Image J.
Dynamic light scattering
Dynamic light scattering was used in addition to NTA and 
scanning electron microscopy for EV sizing. 1.5 μg EVs from a 
4Koliha et al. Melanoma Affects Plasma EV Composition
Frontiers in Immunology | www.frontiersin.org July 2016 | Volume 7 | Article 282
primary melanoma cell line or 10 μg plasma EVs were diluted 
in 500 μl distilled water and measured at the Delsa nano HC 
(Beckman Coulter). To determine the EV size, the average of 
three independent measurements was calculated.
Multiplex Bead-Based Platform
Polystyrene beads were labeled with two dyes in varying amounts 
to distinguish 39 different bead populations by flow cytometry in 
the FITC and PE channel (32). Each bead population was coupled 
with a different capture antibody (Table S3 in Supplementary 
Material).
Approximately 800 beads per bead population were incubated 
with isolated EVs or cell culture supernatant at 4°C overnight in 
100 or 300 μl, respectively. To adjust the volume of different sam-
ples PAP buffer was used consisting of PBS with 0.1% Pluronic 
(Gibco, 24040-032) and 0.09% azide (VWR, 1.06688.0250). To 
remove unbound EVs, the beads were washed in PAP and pel-
leted at 3,000 × g for 5 min. The beads were resuspended in 100 μl 
PAP and bound EVs were stained with a cocktail of 0.5 μg each 
of APC-conjugated anti-CD9 (clone SN4, Miltenyi Biotec Cat# 
130-103-956 Lot# RRID:AB_2571528), anti-CD63 (clone H5C6, 
Miltenyi Biotec Cat# 130-100-182 Lot# RRID:AB_2571529), 
and anti-CD81 (clone JS-81, BD Biosciences Cat# 551112 Lot# 
RRID:AB_398491) antibodies.
Flow cytometry analysis
For analysis, the flow cytometer MACSQuant Analyzer 10 with 
the corresponding software (Miltenyi Biotec) was used.
For cell analysis, 5  ×  105 monocytes and 5  ×  105 moDCs 
were each stained with CD14-FITC (Miltenyi Biotec Cat# 130-
080-701 Lot# RRID:AB_244303), CD40-APC (Miltenyi Biotec 
Cat# 130-094-137 Lot# RRID:AB_10828346), and CD86-PE 
(Miltenyi Biotec Cat# 130-094-877 Lot# RRID:AB_10839702) 
or with CD209-APC (Miltenyi Biotec Cat# 130-092-871 Lot# 
RRID:AB_871640). Stainings were performed in a total volume 
of 110 μl with final antibody dilutions of 1:11 with FcR Blocking 
reagent (Miltenyi Biotec) in PEB (PBS with 0.5% BSA and 2 mM 
EDTA) for 10  min at 4°C. After washing with PEB, cells were 
resuspended in 100 μl PEB, dead cells were stained with propidium 
iodide and the sample was analyzed by MACSQuant Analyzer 
10 (Miltenyi Biotec). At least 10,000 events were measured per 
sample. In the forward/side scatter, debris was excluded from the 
analysis. Dead cells were identified by staining with propidium 
iodide and excluded from the analysis. Gates were set consider-
ing the stainings with isotype control antibodies. For evaluation, 
MACSQuantify software version 2.6 (Miltenyi Biotec) was used.
For the multiplex platform, appropriate settings were selected 
as previously described (32). The signals depicted in the fig-
ures are background corrected signals or normalized signals. 
Background corrected signals were calculated for each bead type 
by subtracting the signal obtained with beads and the staining 
cocktail from the signal of captured and stained EVs. For the 
NK cell derived EVs isolated from medium with human AB 
serum, an additional background control was used: the protein 
amount of an equivalent volume of medium, including human 
AB serum without exposure to cells was used and the signals were 
subtracted from the EV sample signals. Signals were normalized 
to the mean signal intensity obtained with the anti-CD9, CD63, 
and CD81 beads.
statistics
To create the heat map depicted in Figure 3, the public software 
Multi Experiment Viewer (MeV) was applied (38). For unsu-
pervised hierarchical clustering, average linkage clustering was 
performed with the distance metric approach using Pearson 
correlation, including optimization of sample leaf order.
T-test calculations were performed using Microsoft Excel.
resUlTs
size and concentration of isolated 
extracellular Vesicles
Extracellular vesicles from plasma of healthy donors or mela-
noma patients as well as from primary melanoma cell lines and 
isolated primary human blood cells were enriched for exosomes 
using ultracentrifugation. We determined the size of the iso-
lated EVs by nanoparticle tracking analysis (NTA, Figure 1A), 
scanning electron microscopy (Figure  1B), and dynamic light 
scattering (Figure S1 in Supplementary Material). The peaks of 
the size distribution for the different EV types ranged from 90 
to 140  nm (Figure  1A). NTA was also used to count particles 
and to calculate the protein amount per particle after protein 
quantification by BCA assay (Figure 2). Interestingly, we found 
the lowest protein amount per particle for EVs isolated from the 
melanoma cell culture supernatant. It was about 50 times lower 
as compared to most of the EV preparations from primary cells 
or plasma. The tumor cells might produce EVs with lower protein 
content or the other EV preparations might be contaminated with 
protein aggregates resulting in higher calculated protein amounts 
per particle.
Extracellular vesicles isolated from platelets, moDCs and 
T cells showed similar protein contents per particle as the plasma 
vesicles. By contrast, B cell EVs seemed to have a lower protein 
content. After B cell stimulation, EVs from resting and activated 
B cells did not differ significantly (p =  0.22, two-tailed paired 
T-test) in their protein amount (Figure 2).
surface Protein Profiles of Blood  
cell-Derived eVs and Plasma eVs
Exosomes are known to incorporate proteins, including cell type-
specific markers from their parental cell. To investigate the origin 
of EVs circulating in blood, the protein profiles of plasma EVs 
and blood cell-derived EVs were analyzed.
The so-called exosome markers CD63 and CD82 were broadly 
detected, whereas CD9 and CD81 were present less frequently 
(Figure 3, black arrows). CD9 signals were remarkably low on 
NK cell-derived EVs and CD81 was absent on platelet EVs. T cell 
EVs showed only low signal intensities for most of the markers, 
including CD9 and CD81, most likely due to the low EV yield. 
Other surface proteins, such as CD29 (integrin beta1), CD24, 
HLA-ABC, and HLA class II were commonly detected.
Unsupervised hierarchical clustering grouped the EV samples 
according to their surface protein profiles and the originating 
FigUre 2 | Protein amount per particle of different eV samples. Particle concentration was defined using nanoparticle tracking analysis (NTA); protein 
concentration was measured by BCA Assay. Melanoma EVs were isolated from primary melanoma cell cultures of three patients. Citrate/Heparin indicate the 
anticoagulant used for plasma preparation.
FigUre 1 | sizing of isolated eVs. (a) Superimposed nanoparticle tracking analyses of EVs from healthy plasma, unstimulated B cells, Calcium Ionophore-
stimulated platelets, melanoma cell culture, and mature monocyte-derived dendritic cells. (B) Scanning electron microscopy of EVs isolated from melanoma cell 
culture. Arrows point at EVs.
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cells (Figure  3). Within the selected surface proteins used for 
this assay, we detected cell-type-specific markers, such as CD2 
and CD8 for T cell EVs, CD19 on B cell EVs, CD14 on monocyte 
EVs, or CD40, CD80, CD83, and CD86 on moDC-derived EVs. 
The platelet markers CD41b, CD42a, CD61, and CD62P were 
detected in most of the EV samples (Figure 3, red arrows) except 
from T cells and NK cells. T cell EVs showed generally low signal 
intensities and the NK cell EVs were isolated from NK cells after 
14 days in culture with media changes. Due to the sticky nature 
of platelets, it is hard to completely avoid platelet contaminations 
if cells are isolated from buffy coats. Still, we preferred to use 
primary cells for the generation and analysis of EVs as EVs from 
cell lines might resemble an artificial phenotype. As a precaution, 
we would assign positive signals on platelet marker beads for 
non-platelet or plasma samples to platelet-derived EVs.
In the plasma samples, we observed some surface proteins 
corresponding to EVs from the cultured primary cells. We found 
the platelet markers CD41b, CD42a, CD61, and CD62P, the T cell 
or NK cell marker CD8, and finally CD40 and CD86 that implied 
the existence of dendritic cell EVs and B cell EVs. Three out of 
FigUre 3 | heat map depicting the surface protein profiles of eVs from different primary blood cells and plasma of healthy donors and melanoma 
patients. Background corrected signals were used. The range indicator is limited to signals below 10 MFI to draw the attention to the presence or absence of 
signals instead of variations of strong signals.
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the 13 plasma vesicle preparations from healthy donors showed 
 signals for CD19 that hint at B cell EVs in plasma. In summary, 
the surface proteins on plasma EVs indicated that mainly plate-
lets, T cells, NK cells, dendritic cells, and B cells contribute to the 
pool of plasma EVs (Figure 3).
The composition of surface Proteins on 
eVs is Modified by cell stimulation
Extracellular vesicles circulating in blood might derive from rest-
ing as well as activated cells. The activation of some cells leads 
to an increased EV secretion and might also impact the protein 
composition of the secreted EVs. As an example, we isolated EVs 
from resting T cells and from stimulated T cells.
We observed stronger signals for each analyzed surface protein 
for EVs from stimulated T cells as compared to the unstimulated 
control samples. As the same protein amounts were used for the 
assay, the higher signals could be due to a lower proportion of 
potentially co-purified protein aggregates or due to an increased 
proportion of the detected surface proteins within the total pro-
tein amount. However, the signal increase was not statistically 
significant (data not shown).
By contrast, EVs from stimulated B cells showed significantly 
altered signals for 12 surface proteins in comparison to EVs from 
unstimulated B cells (Figure  4). Eleven out of 12 significantly 
changed proteins showed a stronger signal, while the CD81 
signal was weaker on EVs from stimulated B cells as compared 
to EVs from resting B cells. As the protein load per vesicle was 
FigUre 5 | Protein profiles of (a) monocytes, immature and mature 
moDcs after dead cell exclusion by Pi and of (B) the respective eVs.
FigUre 4 | normalized protein profiles of B cell-derived eVs without 
(gray dots) and after cell stimulation with cD40 ligand and il-4 (black 
squares) for 4 days, *p < 0.05, **p < 0.01 (two-tailed paired T-test).
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comparable with and without B cell stimulation (Figure 2), the 
data indicate that the composition of the EVs was changed as a 
consequence of the stimulation.
Given that CD19, CD40, and CD69 are selectively loaded on 
EVs of stimulated B cells (Figure 4), the parallel detection of these 
surface proteins on plasma EVs from three donors (Figure  3) 
supports the presumption that some plasma vesicles might be 
secreted by activated B cells.
The composition of surface Proteins on 
eVs is Modified by moDc Differentiation 
and Maturation
As dendritic cells constitutively secrete EVs, plasma EVs might 
also derive from immature and mature dendritic cells. Therefore, 
EVs from monocytes, immature moDCs, and mature moDCs 
were analyzed.
The monocyte marker CD14 was detected on monocytes and 
their secreted vesicles while its signal intensity decreased during 
moDC differentiation on cells as well as on EVs (Figure 5). An 
opposing trend appeared for the activation markers CD40 and 
CD86 as the median signal intensities increased markedly on 
the moDCs during maturation and on the corresponding EVs 
(Figure 5), indicating that the activation markers are transferred 
from the cells to their EVs. The signals for CD209 (DC-SIGN) 
decreased during maturation on moDCs and later also on the 
respective EVs (Figure  5). In summary, activation markers 
known to be modulated during the generation of moDCs were 
also observed on the secreted EVs.
Plasma EVs from healthy donors showed weak signals for 
CD209 and CD86 and plasma EVs from five donors were positive 
for CD40. It should be considered with caution whether CD40+ 
EVs in plasma might derive from dendritic cells as they might 
also derive from activated B cells.
Phenotyping of Plasma eVs from 
Melanoma Patients
We aimed to investigate whether the composition of EVs in the 
plasma of melanoma patients is different as compared to healthy 
controls and whether melanoma-specific EVs can be detected.
The plasma EVs of eight melanoma patients appeared distinct 
from heparin plasma EVs from nine healthy donors. Despite the 
use of different anticoagulants, the difference can also be seen 
between heparin melanoma plasma EVs and citrate plasma 
EVs from 13 healthy donors in the cluster analysis of surface 
proteins (Figure 3). To identify surface proteins on EVs that led 
to this separation, we calculated the fold change for each of 39 
investigated surface proteins between heparin plasma EVs from 
healthy donors and melanoma patients. The signal intensities 
for five surface proteins differed by at least 1.3-fold, namely the 
general exosome marker CD9 as well as CD8, CD29, and the 
platelet markers CD42a and CD62P (Figure 6A). The signals for 
CD9, CD29, and CD42a were significantly increased (p < 0.05, 
two-tailed T-test, unequal variances; 1.4-fold, 2.9-fold, and 1.9-
fold stronger, respectively). The signals for CD8 and CD62P were 
FigUre 6 | normalized signal intensities of (a) exosome markers and surface proteins that differ between plasma eVs of healthy controls or 
melanoma patients and (B) potential markers for melanoma eVs. REA and mIgG1: isotype controls. *p < 0.05, **p < 0.01 (two-tailed T-test).
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significantly decreased (p < 0.05; p < 0.01) and 2.2- and 2.0-fold 
lower, respectively, for EVs from melanoma patients as compared 
to healthy donors.
To exclude other variables than melanoma that may influ-
ence the surface protein signals for plasma EVs, we reanalyzed 
the data after splitting the samples of healthy donors by sex, 
age, and smoking habits. We saw only minor impacts on few 
EV protein signals (Figures S2, S3, and S4 in Supplementary 
Material). Additionally, we evaluated the impact of a potential 
delay between venipuncture and plasma isolation by preparing 
plasma from healthy donors with heparin as anticoagulant for 
different time points after blood draw and analyzed the isolated 
EVs. The calculation of correlation coefficients that involved 39 
surface proteins showed that the time between blood draw and 
plasma isolation had hardly any effect (Table S1 in Supplementary 
Material). Two (CD29 and CD42a) out of the five proteins that 
showed signal differences between heparin plasma EVs from 
melanoma patients and healthy donors also showed changed sig-
nals between heparin and citrate plasma EVs from healthy donors 
(Figure 6A and Figure S4 in Supplementary Material). However, 
the average signal differences between healthy citrate plasma EVs 
and melanoma heparin plasma EVs for each of the five markers 
(CD9, CD8, CD29, CD42a, and CD62P) were at least equal or 
even more pronounced as compared to the differences of the 
heparin plasma samples (Figure S4 in Supplementary Material).
CD29 was detected on each EV preparation and can, therefore, 
not be attributed to a specific parental cell type. We detected CD42a 
on platelet EVs while CD81 was lacking (Figure  3) and, thus, 
considered an elevated proportion of platelet EVs in melanoma 
plasma. However, lower signals for the platelet marker CD62P 
on plasma EVs from melanoma patients might rather indicate 
a changed loading of platelet EVs than a higher proportion of 
platelet EVs. We detected CD8 on EVs from T cells and NK cells 
(Figure  3). Potentially, less EVs from cytotoxic cells, such as 
T cells and NK cells are the reason for the lower CD8 signals in 
melanoma plasma.
Surprisingly, we did not observe significant differences for the 
suggested melanoma markers melanoma-associated chondroitin 
sulfate proteoglycan (MSCP), CD146 (Mel-CAM), or CD49e 
(integrin α5) between plasma EVs from melanoma patients and 
healthy donors. All three markers were clearly detectable on mela-
noma EVs isolated from primary melanoma cell culture (data not 
shown). But only the CD49e signal appeared higher for plasma 
EVs from five of the eight melanoma patients (Figure  6B). By 
spike in experiments, we determined the sensitivity of the assay 
to be 1% for MCSP or CD146 of melanoma cell culture-derived 
EVs in plasma EV samples from healthy donors (Figure S5 in 
Supplementary Material). The higher detection limit of 10% for 
CD49e raises the question whether the CD49e signal in the plasma 
samples of melanoma patients could be addressed to tumor cells. 
As the integrin CD49e is not specific for tumor cells, the results 
should be interpreted with care.
As we did not see significant differences between the signal 
intensities for MCSP or CD146 on plasma EVs from melanoma 
patients as compared to healthy controls, we conclude that less 
than 1% of plasma EVs derive directly from melanoma tissue.
In summary, we observed that the signal intensities for five 
surface proteins differed significantly between plasma EVs from 
melanoma patients and healthy donors, but only a minor portion 
of plasma EVs derive from tumor cells.
DiscUssiOn
Vesicles circulating in blood might derive from a variety of cells, 
including tumor cells in patients. It has been shown that immune 
cell-derived exosomes and tumor exosomes influence immune 
response and tumor progression (1, 22, 39, 40). Therefore, we 
focused our analysis on the potential contribution of EVs from 
immune cells and melanoma cells to the pool of EVs in plasma 
from melanoma patients.
As the so-called exosome markers CD9 and CD81 were 
missing on NK cell EVs or platelet EVs, respectively (32), we 
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consider CD63 to be more suitable as general exosome marker. 
We detected CD63 signals also on plasma EVs in contrast to 
Jorgensen and colleagues (41) probably due to the use of an 
alternative antibody clone.
We detected the glycoproteins CD29 (integrin beta1) and 
CD24 on almost every EV preparation. CD29 is known as an 
interaction partner of tetraspanins on cells (42–44) and is prob-
ably transferred together with tetraspanins to exosomes during 
their biogenesis. Accordingly, CD29 had already been detected 
on different types of exosomes (45–48). CD24 is a GPI-anchored 
protein that is restricted to lipid rafts and is, therefore, likely also 
found on exosomes (49). According to our results, we suggest 
CD24 and CD29 along with CD63 as common exosome proteins 
that are applicable as staining markers for EVs.
Major histocompatibility complex class I (HLA-ABC) is 
expressed by practically every nucleated cell and has been shown 
to be transferred to exosomes (1). The low signal intensities for 
HLA-ABC on plasma EVs might be due to a high percentage of 
MHC class I weak EVs, such as those secreted by NK cells and 
platelets.
Besides the broadly detected surface proteins on EVs, more 
specific markers were identified that allow to determine cell 
types potentially contributing to the pool of plasma EVs. We 
detected platelet markers (CD41b, CD42a, CD61, CD62P) on 
plasma vesicles in line with previous studies (17, 50), confirming 
the assumption that platelets contribute to the pool of plasma 
EVs. APCs are considered as another source of plasma EVs 
because HLA-DR positive signals had been described for plasma 
EVs captured on anti-CD63-coated beads (17, 18). However, the 
contribution of APCs might have been overestimated because 
we detected HLA class II also on platelet EVs. Therefore, the 
signals for CD40 and CD86, which were detected on moDC-
EVs and B cell EVs, more likely reflect APC-EVs in plasma. 
Additionally, we detected signals for CD8 on plasma EVs, 
implying a contribution of T cells and NK cells to the mixture 
of vesicles in plasma.
Plasma EVs might also give information about cell–cell 
interactions, such as stimulation of immune cells. For example, 
T cell receptor activation had already been shown to upregulate 
the production of exosomes (20, 21). Despite the increased exo-
some release, we did not observe a significantly altered protein 
composition of EVs that could be used to distinguish EVs from 
resting T cells and stimulated T cells. By contrast, we observed 
that the signals of 12 surface proteins were changed on EVs if B 
cells were stimulated. Among the 12 markers, exosomal HLA has 
already been reported to be increased after B cell stimulation (19, 
51). CD20 is known to be downregulated on B cells upon CD40 
activation (52) and has been detected on B cell exosomes (26, 27). 
After B cell activation, CD20 as a B cell co-receptor (53), CD40 
as a co-stimulatory molecule, and CD69 as a known activation 
marker (54) might be transferred via exosomes to resting B cells 
to enhance immune responses.
To analyze EVs of dendritic cells, we used moDCs due to 
the low frequency of dendritic cells in blood, even though it is 
controversial whether in vitro generated moDCs are comparable 
with dendritic cells in blood (55, 56). The signals for HLA class 
II and CD40 on plasma EVs could be an indication of DCs or 
activated B cells.
Comparing EVs from plasma of melanoma patients and healthy 
controls, we found that the signals of 5 out of 39 investigated 
proteins differed significantly and by at least 30%, namely CD9, 
CD8, CD29, CD42a, and CD62P. The platelet markers CD42a and 
CD62p indicate that either the proportion of platelet EVs or the 
loading of platelet EVs is altered in melanoma patients. Platelet 
microparticles were shown to induce metastasis and angiogenesis 
in lung cancer (57) and invasiveness in breast cancer (58). A sur-
plus of platelet EVs might, therefore, indicate tumor progression.
The lower signal for CD8 on melanoma plasma EVs as com-
pared to healthy plasma EVs could be due to less NK or T cell 
EVs. NK cell-derived exosomes are known to carry Fas ligands 
that mediate tumor cell killing (59) and T cell-derived EVs are 
thought to transfer functional miRNAs to APCs to generate 
an immune response (60). EVs from NK cells and T cells are, 
thus, able to support immune responses against tumors. We 
hypothesize that, along with the previously discussed elevated 
proportion of platelet–EVs, a downsized fraction of EVs from 
cytotoxic cells might indicate tumor progression and an attenu-
ated immune response.
We analyzed and tried to exclude technical reasons for the 
altered composition of plasma EVs in melanoma patients. In 
line with Yuana and colleagues, we did not observe increasing 
signals for platelet markers on plasma EVs with time after sample 
preparation (61).
As the melanoma EV samples were isolated from heparin 
plasma, we compared the protein profiles with the protein pro-
files of healthy control EVs prepared also from heparin plasma. 
However, heparin is not able to chelate calcium ions and still allows 
platelet degranulation that leads to EV secretion. Accordingly, 
citrate is recommended in EV research as anticoagulant to 
prevent EV release after blood draw (62, 63). To investigate the 
impact of the anticoagulant on the protein profile of plasma EVs, 
we also included EVs from healthy plasma anticoagulated with 
citrate in our analysis. Differing signals for CD29, and CD42a 
between heparin and citrate plasma EVs from healthy donors 
implied an anticoagulant-mediated effect. However, the differ-
ences for CD29 and CD42a appeared even stronger if healthy 
citrate plasma EV samples were compared to the heparin plasma 
samples of melanoma patients.
Tumor-derived EVs in plasma are discussed as potential 
biomarkers because they were described as “relatively numer-
ous” and easily accessible (64). We could hardly detect signals for 
the potential melanoma markers MSCP or CD146 (Mel-CAM) 
on EVs from plasma of melanoma patients. We also considered 
CD49e (integrin α5) as a potential marker for melanoma-derived 
EVs because it was found to be expressed by melanoma cells (33) 
and we detected CD49e signals on EVs from melanoma cell 
cultures. On plasma EVs, the CD49e signals were increased for 
five out of eight melanoma patients.
However, in EVs isolated from melanoma cell culture, the 
CD49e signal was less pronounced as compared to MSCP or 
CD146. Therefore, we consider the CD49e signal to be related 
to EVs from non-tumor cells because integrins are not tumor 
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specific. We conclude that melanoma EVs are not a major portion 
within the pool of EVs in melanoma patient’s plasma.
For our multiplex platform, we determined a detection limit of 
1% melanoma EVs in plasma. To estimate the tumor size required 
to secrete EVs giving at least 1% of plasma EVs, we considered 
that we isolated on average 7 μg EVs per milliliter whole blood 
from healthy donors. Approximately 80 μg EVs were secreted 
from 109 melanoma cells in culture. Supposing 5 liter blood per 
person and the volume of a melanocyte to be in the range of 
600 μm3 (65), we calculated that a well vascularized melanoma 
of at least 2600 mm3 (e.g., diameter of 28 mm and 4 mm depth) 
in size could give rise to EV numbers that are equivalent to 1% of 
plasma vesicles. Even for stage 3 or 4 patients, the requested tumor 
size would be quite big or many metastasis would be needed to 
sum up to the calculated number of tumor cells. Due to lacking 
signals for the potential melanoma markers MCSP or CD146 on 
plasma EVs from melanoma patients, we conclude that there are 
less than 1% melanoma EVs circulating in these patient’s plasma. 
Interestingly, Laresche and colleagues also were unable to detect 
melanoma microparticles in the plasma of over 100 melanoma 
patients (66).
Taken together, our data indicate that the majority of plasma 
EVs of melanoma patients do not derive directly from the tumor. 
However, differing marker signals for platelets and cytotoxic cells 
on plasma EVs from melanoma patients and healthy donors point 
at an altered proportion or marker loading of EVs. Potentially, 
this variation of plasma EVs is related to enhanced vasculariza-
tion or diminished anti-tumor immune responses. Although we 
investigated only eight patient samples, we observed significant 
differences in plasma EV protein profiles. It will be interesting to 
analyze the plasma EVs of more melanoma patients with different 
tumor stages to investigate whether the composition and protein 
loading of plasma EVs reflect the influence of the immune system 
on tumor progression.
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